Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app could cut phone calls for cancer patients

NCT ID NCT06371911

Symptom relief Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a digital platform called Cureety could reduce the number of phone calls hospital staff need to make to cancer patients before their injectable treatments. 192 adults starting injectable cancer therapy in France were randomly assigned to usual care or usual care plus Cureety. The platform lets patients report symptoms and test results online, potentially flagging only those who need a call.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cureety telemonitoring platform
What this could lead to
If successful, this could reduce hospital staff workload and improve patient convenience during cancer treatment monitoring.
What could go wrong
This is a completed study, but the results are not yet widely known. The benefit may be limited to patients comfortable with technology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

192 people

The number who actually took part.

Started

Apr 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Patients that have provided written informed consent for study participation before any trial-related activities. * Patients aged 18 years or older. * Patients initiating injectable anticancer treatment (chemotherapy, immunotherapy, targeted therapies etc.). * Patients with the capacity, personally (e.g., language and capacity to use the application), and in terms of infrastructure (internet access, possessing a smart phone etc.) to perform Cureety telemonitoring. * Patient affiliated to an appropriate social security system Non-inclusion criteria * Exclusive oral cancer treatment * Patient with dysphonia or difficulty communicating orally * Patient benefiting from injectable cancer treatment as part of a clinical trial * Inability to undergo trial monitoring for geographical, social or psychological reasons * Any associated medical or psychological condition that could compromise the patient's ability to participate in the study * Patient deprived of freedom or under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult patients initiating injectable anticancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult patients initiating injectable anticancer

Contacts and locations

Locations

  • Centre François Baclesse

    Caen, 14000, France

  • Centre de Radiothérapie et Oncologie Médicale d'Osny

    Osny, France

  • Centre hospitalier de Bligny

    Bligny, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.